Gut microbiota in reductive drug metabolism.

Animals Bacteria / metabolism Gastrointestinal Microbiome Humans Pharmaceutical Preparations / metabolism Xenobiotics / metabolism
Alkene reduction Azo reduction Drug metabolism Gut microbiota Keto-reduction N-oxide reduction Nitroreduction Reduction Sulfoxide reduction Xenobiotic

Journal

Progress in molecular biology and translational science
ISSN: 1878-0814
Titre abrégé: Prog Mol Biol Transl Sci
Pays: Netherlands
ID NLM: 101498165

Informations de publication

Date de publication:
2020
Historique:
entrez: 2 6 2020
pubmed: 2 6 2020
medline: 8 5 2021
Statut: ppublish

Résumé

Gut bacteria are predominant microorganisms in the gut microbiota and have been recognized to mediate a variety of biotransformations of xenobiotic compounds in the gut. This review is focused on one of the gut bacterial xenobiotic metabolisms, reduction. Xenobiotics undergo different types of reductive metabolisms depending on chemically distinct groups: azo (-NN-), nitro (-NO

Identifiants

DOI: 10.1016/bs.pmbts.2020.04.002 PMID: 32475528
pubmed: 32475528
pii: S1877-1173(20)30046-6
doi: 10.1016/bs.pmbts.2020.04.002
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0
Xenobiotics 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-93

Informations de copyright

© 2020 Elsevier Inc. All rights reserved.

Auteurs

Yukuang Guo (Y)

Department of Pharmaceutical Sciences, Center for Biomolecular Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, United States.

Hyunwoo Lee (H)

Department of Pharmaceutical Sciences, Center for Biomolecular Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, United States. Electronic address: hlee31@uic.edu.

Hyunyoung Jeong (H)

Department of Pharmaceutical Sciences, Center for Biomolecular Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, United States. Electronic address: yjeong@uic.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Gut microbiota in reductive drug metabolism.
questionsmedicales.fr › Bactéries › Gut microbiota in reductive drug metabolism.
questionsmedicales.fr › Environnement et santé publique › Environnement › Écosystème › Biodiversité › Biote › Microbiote › Microbiome gastro-intestinal › Gut microbiota in reductive drug metabolism.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Gut microbiota in reductive drug metabolism.
questionsmedicales.fr › Préparations pharmaceutiques › Gut microbiota in reductive drug metabolism.
questionsmedicales.fr › Préparations pharmaceutiques › Xénobiotique › Gut microbiota in reductive drug metabolism.